NASDAQ:ATXI - Avenue Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.00
  • Forecasted Upside: 142.91 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.47
▲ +0.06 (2.49%)

This chart shows the closing price for ATXI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avenue Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATXI

Analyst Price Target is $6.00
▲ +142.91% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Avenue Therapeutics in the last 3 months. The average price target is $6.00, with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 142.91% upside from the last price of $2.47.

This chart shows the closing price for ATXI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Avenue Therapeutics. This rating has held steady since October 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2020HC WainwrightReiterated RatingHold$6.00High
10/12/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
5/12/2020HC WainwrightBoost Price TargetBuy$12.00 ➝ $13.00Medium
2/13/2020HC WainwrightReiterated RatingBuy$12.00Medium
5/14/2019HC WainwrightReiterated RatingBuy$11.00High
11/15/2018OppenheimerSet Price TargetBuy$10.00High
8/15/2018HC WainwrightReiterated RatingBuy$11.00Low
8/15/2018OppenheimerSet Price TargetBuy$8.00Low
7/12/2018OppenheimerInitiated CoverageBuy$8.00High
6/25/2018HC WainwrightInitiated CoverageBuy$11.00High
(Data available from 6/21/2016 forward)
Avenue Therapeutics logo
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $2.47
Low: $2.43
High: $2.52

50 Day Range

MA: $4.45
Low: $2.41
High: $7.11

52 Week Range

Now: $2.47
Low: $2.22
High: $12.34

Volume

4,883 shs

Average Volume

308,362 shs

Market Capitalization

$41.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Avenue Therapeutics?

The following sell-side analysts have issued research reports on Avenue Therapeutics in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ATXI.

What is the current price target for Avenue Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Avenue Therapeutics in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 142.9%. HC Wainwright has the highest price target set, predicting ATXI will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Avenue Therapeutics in the next year.
View the latest price targets for ATXI.

What is the current consensus analyst rating for Avenue Therapeutics?

Avenue Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATXI, but not buy more shares or sell existing shares.
View the latest ratings for ATXI.

What other companies compete with Avenue Therapeutics?

How do I contact Avenue Therapeutics' investor relations team?

Avenue Therapeutics' physical mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company's listed phone number is 781-652-4500 and its investor relations email address is [email protected] The official website for Avenue Therapeutics is www.avenuetx.com.